Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting

Salvage radiotherapy (sRT) after radical prostatectomy (RP) is the standard of care treatment for prostate cancer (PCa) patients experiencing biochemical recurrence (BCR). Delivery of early sRT (initiated at prostate-specific antigen (PSA) level below 0.25 ng/mL) is associated with a reduction in all-cause mortality risk compared to men who received sRT when PSA levels are above this threshold [ 1 ]. Treatment intensification is needed for this latter group of patients and those with other unfavorable disease characteristics (such as a rapid PSA doubling time - PSA-DT and ISUP group ≥ 4) to improve clinical outcomes.